Clinical Trial Update: Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder [Phase 1]

View source ↗

Summary

A Phase 1 safety and pharmacodynamic study of ABT-436 in Major Depressive Disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• ABT-436

Snippet

Sponsor: AbbVie | Conditions: Major Depressive Disorder | Phase 1 | Status: COMPLETED